Top Markets
Coin of the day
Antisense Therapeutics Limited Antisense Therapeutics Limited

Antisense Therapeutics Limited

ANP
Classifica tra le azioni #33635
Antisense Therapeutics Limited, an Australian company headquartered in Toorak... Antisense Therapeutics Limited, an Australian company headquartered in Toorak and founded in 2000, specializes in the research and advancement of innovative antisense pharmaceutical drugs. Its primary pipeline asset, ATL1102, is an antisense inhibitor designed to target CD49d, which is currently in Phase II clinical trials for treating various inflammatory conditions such as multiple sclerosis, Duchenne Muscular Dystrophy, and asthma. Another promising therapeutic in their portfolio is ATL1103, a second-generation antisense drug that aims to block growth hormone receptor expression, thereby lowering insulin-like growth factor-I levels in the blood, and has completed Phase II clinical trials for conditions stemming from excessive growth hormone action.
Prezzo delle azioni
$0.03702159
Ultima sincronizzazione: 2024-01-29
Capitalizzazione di mercato
$7.21M
Variazione (1 giorno)
-3.08%
Variazione (1 anno)
0.00%
Paese
AU
Scambia Antisense Therapeutics Limited (ANP)

Categoria

Storico del prezzo dell'azione per Antisense Therapeutics Limited (ANP)
Prezzo di chiusura più alto: $0.04 il 2024-01-01

Prezzo di chiusura più basso: $0.89 il 2001-12-01
Storico del prezzo dell'azione di Antisense Therapeutics Limited dal 2001 al 2026
Andamento annuale del prezzo dell'azione
Anno Performance
2024 3.20%
2023 -37.05%
2022 -56.36%
2021 59.69%
2020 44.65%
2019 191.58%
2018 3.71%
2017 -27.93%
2016 -45.26%
2015 -30.97%
2014 -50.82%
2013 16.96%
2012 -52.56%
2011 252.85%
2010 -78.09%
2009 107.28%
2008 -31.61%
2007 18.43%
2006 15.79%
2005 -72.58%
2004 4.39%
2003 129.21%
2002 -69.82%
2001 0.00%
Prezzo dell'azione per aziende simili o concorrenti
Azienda Prezzo dell'azione Variazione 1a% Il paese
$171.67 -
DE
$161.44 23.08%
DE
$35.97 20.03%
JP
$225.32 37.71%
CH
$20.95 11.92%
IN